AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion 5.6 mg/kg Q3W
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion 4.8 mg/kg Q3W
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at 80 mg once daily
Study NCT05084027 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: venetoclax combining with fludarabine and melphalan
Description: Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
Study NCT05689320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: EMA-based intervention
Description: This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
Study NCT05427669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Study NCT04938895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Respondents Exposure to a Photo
Description: Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
Study NCT04852744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups.
Study NCT05077852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urethrocystoscopy
Description: Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
Study NCT06251128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Self management Program
Description: Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants
Study NCT06528678 — intervention group
Intervention type: DEVICE
Intervention: Intraocular lens
Description: Lens exchange with an intraocular lens
Study NCT04868409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suxamethonium
Description: 1 mg/kg for tracheal intubation after 60 seconds
Study NCT04868409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 1 mg/kg for tracheal intubation after 60 seconds
Study NCT05555082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: 10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
Study NCT00939705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study NCT00939705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study NCT06370299 — intervention group
Intervention type: OTHER
Intervention: (exposure of) MDR carriage
Description: The difference in exposure between the two groups is the carriage or non-carriage of multidrug resistant gram negative bacilli.
Study NCT04897971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Medium enriched for newly synthesized antibodies in spine infection
Description: Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
Study NCT05114226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
Study NCT06245616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of olive pomace olive oil by alzheimer's patients
Description: Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
Study NCT06245616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of olive pomace olive oil by alzheimer's patients
Description: Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
Study NCT06245616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of high-oleic sunflower oil by alzheimer's patients
Description: Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
Study NCT06245616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of high-oleic sunflower oil by alzheimer's patients
Description: Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
Study NCT04797247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: PCSK9 inhibitor
Study NCT04797247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lerodalcibep
Description: PCSK9 inhibitor
Study NCT05837559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Description: Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Study NCT05837559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Description: Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Study NCT06306495 — intervention group
Intervention type: OTHER
Intervention: International Physical Activity Survey
Description: Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
Study NCT05729256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Intervention
Description: Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
Study NCT05729256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice and Information
Description: Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
Study NCT05332561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: Arm 1
Study NCT05332561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Arm 2
Study NCT05332561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Arm 3
Study NCT05332561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Arm 4
Study NCT05332561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Arm 5
Study NCT05332561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab/pertuzumab
Description: Arm 6
Study NCT06533904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Cryoablation of Intercostal Nerves
Description: Percutaneous Cryoablation of Intercostal Nerves
Study NCT06533904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multi-modal pain regimen
Description: Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
Study NCT06533904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal pain regimen
Description: Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
Study NCT06542042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NAS, NGS and Laboratory tests
Description: Using three diffrent detection methods and comparing their efficiency
Study NCT05727605 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test
Description: Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
Study NCT05727605 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy
Study NCT05727605 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI
Description: Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
Study NCT05727605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Toxicity scoring
Description: During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
Study NCT05499923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Debonding
Description: Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
Study NCT06281548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESTART
Description: Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
Study NCT05692921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Home Monitoring (RHM)
Description: A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
Study NCT05692921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Response Nursing
Description: A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
Study NCT04619433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
Description: Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
Study NCT04619433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camrelizumab;Pemetrexed and Carboplatin;Placebo
Description: Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
Study NCT05385263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion\<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
Study NCT06578832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: physical and chemical methods
Description: Salivary flow rate, pH, buffering capacity
Study NCT06578832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical methods
Description: Total oxidant and antioxidant capacities
Study NCT06578832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical tests
Description: urea, calcium, potassium, phosphorus
Study NCT06578832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Health Habits
Description: Tooth brushing frequency Dental floss usage Annual dentist visits
Study NCT06578832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Findings
Description: DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries.~DDE Index: Developmental Defects of Enamel index. BAKH Index: Basic Anatomic Keratinization Hierarchy, typically used in specific studies.~DI (Debris Index): Assesses oral hygiene based on the amount of debris on the teeth.~CI (Calculus Index): Measures the amount of calculus (tartar) on the teeth. OHI-S (Simplified Oral Hygiene Index): Assesses oral hygiene based on the presence of debris and calculus.~MGI (Modified Gingival Index): Assesses the severity of gingivitis based on inflammation.
Study NCT06578832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment
Description: KINDLR Scale: Used to assess disease-related quality of life from both the child's and the parent's perspectives.
Study NCT06577909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.
Study NCT06577909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.
Study NCT06577909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg 400mg/kg (≤20g for the total dose) per day for 5 days, and repeated in the case of lack of response by day 14
Study NCT05443555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
Study NCT05443555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
Study NCT05454423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication
Description: -Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding
Study NCT05454423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional physical therapy + anti-hyperuricemia medication
Description: traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17.
Study NCT05433337 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital ACT
Description: Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
Study NCT06575803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical measurements and evaluation
Description: clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics
Study NCT06574750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)
Description: Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
Study NCT06574750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JuvedermⓇ (Q-Med AB, Uppsala, Sweden)
Description: Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
Study NCT06574711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil yogurt
Description: Sacha inchi oil was incorporated into a nonfat yogurt acting as a source of linolenic acid
Study NCT06574711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid palm oil yogurt
Description: Interspecific hybrid palm oil was incorporated into a nonfat yogurt as a source of bioactive compounds
Study NCT06574711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control yogurt
Description: Conventional full-fat yogurt
Study NCT04730596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.
Study NCT04730596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.
Study NCT04730596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline in a labeled syringe
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: IV
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: IV
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: IV
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: IV
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: IV